September 22, 2016
Key Goal: To Promote Research Collaboration Among Faculty at UM SOM and other UMB Schools
The Institute for Global Health (IGH) at the University of Maryland School of Medicine (UM SOM) will hold its first Global Health Summit on September 26.
The event, which took place in the SMC Campus Center, sought to foster collaboration among scientists and promote new and innovative global health research at UM SOM, as well as at other schools at the University of Maryland, Baltimore (UMB). Faculty and staff from UM SOM, as well as other schools attended the event.
Among those who will spoke were IGH founding director Christopher Plowe, MD, MPH, FASTMH, the Frank M. Calia, MD Professor of Medicine, UM SOM Dean E. Albert Reece, MD, PhD, MBA, and Kathleen Neuzil, MD, MPH, FIDSA, who is director of the Center for Vaccine Development at IGH, as well as deputy director of IGH.
The event included a range of presentations from departments at UM SOM. Participants also had an opportunity to take part in small group discussions about strategies to promote global health research on campus. The topics included promoting collaboration, expanding research to non-communicable diseases and creating opportunities for knowledge transfer.
“We’re doing fantastic research already,” said Dr. Plowe. “But we wanted to spread the word among our entire UM SOM faculty, and UMB as well, that we’re eager to work together across disciplines. Global health encompasses so many areas that we can do much, much more. So we need partners.”
In addition to Dr. Plowe and Dr. Neuzil, other faculty members talked about the potential for global health research in their subject areas:
- Miriam Laufer, MD, MPH, associate director for Global Health at IGH and director of IGH-Malawi;
- Robert Redfield, MD, director of the Institute of Human Virology (IHV) Division of Clinical Care and Research;
- Clement Adebamowo, BM, ChB, ScD of IHV’s Division of Epidemiology and Prevention;
- Brian Browne, MD and Terrence Mulligan, DO, MPH, both of the Department of Emergency Medicine;
- Melissa McDiarmid, MD, MPH, director of the Department of Medicine’s Division of Occupational and Environmental Medicine;
- Maureen Black, PhD, director of the Department of Pediatrics Division of Growth and Nutrition;
- Gerard Slobogean, MD, MPH, from the Department of Orthopaedics and the R Adams Cowley Shock Trauma Center;
- Doee Kitessa, MD, from the Department of Obstetrics, Gynecology and Reproductive Sciences;
- Samer El-Kamary, MBChB, MS, MPH, of the Department of Epidemiology and Public Health;
IGH was established in 2015, bringing together an impressive team of researchers with decades of experience in a variety of areas, including vaccines, malaria, and emerging diseases. The institute focuses on vaccine development and malaria research, and consists of the Center for Vaccine Development (CVD) and the Division of Malaria Research (DMR).
With the ultimate aim of global malaria eradication, DMR focuses on the prevention and treatment of malaria, which infects 200 million people a year. It develops and deploys innovative tools for malaria treatment, prevention and surveillance. Working in its Baltimore laboratories and at field sites in Mali, Burkina Faso, Malawi and Myanmar, it designs and leads clinical trials of drugs and vaccines, and applies molecular and genomics approaches to track drug resistance and malaria transmission.
Dr. Plowe, who has been studying malaria for more than 30 years, joined the CVD faculty in 1995, building a multidisciplinary malaria research group that works around the world. Dr. Neuzil, an expert in the study of vaccines, was previously a professor at the University of Washington, and directed vaccine access and delivery at PATH, an international nonprofit global health organization based in Seattle.
IGH has already had several successes. Last year, Dr. Plowe and his colleague and wife, Myaing Myaing Nyunt, MD, MPH, PhD, assistant professor of medicine and director of IGH’s efforts in Myanmar, helped engineer an unprecedented meeting to battle malaria in Myanmar. A diverse array of groups in the country, many with long histories as adversaries, met in Washington D.C. to discuss strategies to eradicate malaria in Myanmar. The groups agreed to cooperate on a long-term plan to eliminate malaria, which is a major problem in many parts of the country. .
IGH also focuses on developing the skills and expertise of those abroad who are on the front lines in the war against infectious and other global diseases. This spread of technical and scientific knowledge will allow less developed countries to create sustainable improvements in public health, which last beyond the end of studies by researchers at western institutions.
About the University of Maryland School of Medicine
The University of Maryland School of Medicine was chartered in 1807 and is the first public medical school in the United States and continues today as an innovative leader in accelerating innovation and discovery in medicine. The School of Medicine is the founding school of the University of Maryland and is an integral part of the 11-campus University System of Maryland. Located on the University of Maryland’s Baltimore campus, the School of Medicine works closely with the University of Maryland Medical Center and Medical System to provide a research-intensive, academic and clinically based education. With 43 academic departments, centers and institutes and a faculty of more than 3,000 physicians and research scientists plus more than $400 million in extramural funding, the School is regarded as one of the leading biomedical research institutions in the U.S. with top-tier faculty and programs in cancer, brain science, surgery and transplantation, trauma and emergency medicine, vaccine development and human genomics, among other centers of excellence. The School is not only concerned with the health of the citizens of Maryland and the nation, but also has a global presence, with research and treatment facilities in more than 35 countries around the world.
Contact
Office of Public Affairs
655 West Baltimore Street
Bressler Research Building 14-002
Baltimore, Maryland 21201-1559
Contact Media Relations
(410) 706-5260
Related stories
Thursday, July 02, 2020
UMSOM Researchers Help Weigh Role of Human Challenge Studies for COVID-19 Vaccine Development
Members of the National Institutes of Health’s (NIH) Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) Working Group, which includes Kathleen Neuzil, MD, MPH, DTPH, the Myron M. Levine, MD, DTPH Professor in Vaccinology and Director of the Center for Vaccine Development and Global Health (CVD) at the University of Maryland School of Medicine (UMSOM), assessed the practical considerations and prerequisites for using controlled human infection models (CHIMs) to support development of a SARS-CoV-2 Vaccine.
Friday, September 20, 2019
UM School of Medicine's Center for Vaccine Development and Global Health Receives NIH Contract of up to More than $200 Million for Influenza Research
Kathleen Neuzil, MD, MPH, Professor of Medicine and Pediatrics and Director of the Center for Vaccine Development and Global Health (CVD) at the University of Maryland School of Medicine (UMSOM) and Dean E. Albert Reece, MD, PhD, MBA, announced that CVD has been awarded a contract from the National Institute of Allergy and Infectious Diseases (NIAID), with total funding up to more than $200 million over seven years if all contract options are exercised.
Friday, March 08, 2019
UMSOM Researchers Unveil Progress and Challenges in Introducing Typhoid Conjugate Vaccine in Sub-Saharan Africa and Asia
Each year there are nearly 11 million cases of typhoid, a disease that is spread through contaminated food, drink and water. Researchers at the University of Maryland School of Medicine are leading an international consortium that is studying the impact of a typhoid conjugate vaccine (TCV) in an effort to accelerate introduction of the vaccine in countries in sub-Saharan Africa and Asia where there is a high burden of typhoid.
Monday, December 03, 2018
UMSOM and Groupe De Recherche Action En Sante Begin Second Typhoid Conjugate Vaccine Study in Africa
A new study has been launched in Burkina Faso for Bharat Biotech’s typhoid conjugate vaccine (TCV). It is the second clinical study underway in Africa for the vaccine and the first in West Africa. The vaccine study is a joint effort by the Center for Vaccine Development and Global Health (CVD) at the University of Maryland School of Medicine, (UMSOM) and Groupe de Recherche Action en Santé (GRAS) in Burkina Faso.
Friday, November 02, 2018
UMSOM Global Health Expert Named to Prestigious World Health Organization Immunization Panel
Kathleen Neuzil, MD, MPH, Professor of Medicine and Pediatrics and Director of the Center for Vaccine Development and Global Health (CVD) at the University of Maryland School of Medicine (UMSOM), has been named to the World Health Organization’s (WHO) Strategic Advisory Group of Experts (SAGE) on Immunization.
Monday, April 23, 2018
UM School of Medicine Launches Newly Organized Center for Vaccine Development and Global Health Under Leadership of International Vaccine Expert Dr. Kathleen Neuzil
University of Maryland School of Medicine (UMSOM) Dean E. Albert Reece, MD, PhD, MBA, announced today the launch of a newly organized Center for Vaccine Development and Global Health (CVD). The new Center will be led by UMSOM Professor of Medicine and Pediatrics, Kathleen Neuzil, MD MPH, FIDSA, one of the world’s most influential research scientists and advocates in vaccine development and policy.
Thursday, September 28, 2017
UM SOM Vaccine Expert Warns of Risks of Influenza to Older Populations
“Protect yourself and others by getting the flu shot” was the message from Kathleen Neuzil, MD, MPH, FIDSA, Director of the Center for Vaccine Development (CVD) at the University of Maryland School of Medicine (UM SOM). Dr. Neuzil was among the speakers at a press conference hosted by the National Foundation for Infectious Diseases. U.S. Secretary of Health and Human Services, Thomas E Price, MD, also spoke at the press conference and urged people to get their flu shot. The panel members all received their flu shots following the press conference.
Monday, May 15, 2017
U.S. CDC Recommends Use of Cholera Vaccine Developed by University of Maryland School of Medicine
A cholera vaccine developed by scientists at the University of Maryland School of Medicine’s Center for Vaccine Development (CVD) has been recommended by the U.S. Centers for Disease Control and Prevention (CDC) for use as a protection for U.S. adults traveling to areas with cholera. The CDC’s latest recommendation was published on May 11, in Morbidity and Mortality Weekly Report.
Thursday, May 04, 2017
UM School of Medicine Researchers Receive $9 Million Grant for Malaria Research
The University of Maryland School of Medicine has been awarded an International Center of Excellence for Malaria Research (ICEMR) grant by the National Institutes of Health’s National Institute of Allergy and Infectious Diseases (NIAID), one of seven ICEMRs awarded worldwide. With funding of more than $9 million over seven years, the grant will be used to research and develop new tools to help eliminate drug-resistant malaria in Myanmar and neighboring countries in Southeast Asia.
Thursday, November 10, 2016
International Consortium Receives $36.9 Million Grant to Fight Typhoid
Typhoid fever, a bacterial infection that causes high fever and other disabling symptoms, remains a serious global problem in the developing world: it kills almost a quarter of a million people annually, and infects about 21 million.
Thursday, August 04, 2016
UM SOM is Center Stage in Testing National Institutes of Health Zika Vaccine
UM SOM'S Center for Vaccine Development, tapped previously for Ebola vaccine, now steps up to help develop first Zika vaccine.
Wednesday, July 06, 2016
UMSOM Begins Malaria Vaccine Trial in Burkina Faso
Malaria is one of the world’s deadliest diseases: it infects hundreds of millions of people every year, and kills about half a million, most of them under five years of age.
Wednesday, June 29, 2016
UM SOM Researchers Awarded Grant to Use Innovative Alternative to Autopsies to Better Understand Child Mortality
Kathleen Neuzil, MD, MPH, director of the Center for Vaccine Development (CVD) at the University of Maryland School of Medicine (UM SOM), and UM SOM Dean E. Albert Reece, MD, PhD, MBA, announced today that CVD has been awarded a large grant from the Bill & Melinda Gates Foundation for research that will help determine why so many children under five are dying in the world’s poorest countries. The grant will fund use of an innovative alternative to traditional autopsy known as minimally invasive tissue sampling. The technique, which involves the collection of tissue samples with fine needles, allows researchers to quickly identify the cause of death, and help illuminate ways to save lives and improve the health of children in these vulnerable areas.
Friday, June 24, 2016
Investiture Celebrates the Courage and Passion of Two University Warriors
In a packed Westminster Hall, with one of the largest audiences to date for any investiture ceremony, Christopher Plowe, MD, MPH, was named the Frank M. Calia, MD Professor of Medicine.
Tuesday, April 12, 2016
UM SOM Researcher Dr. Kathleen Neuzil Honored by Vanderbilt University School of Medicine
The Vanderbilt University School of Medicine (VUSM) has announced that Kathleen Neuzil, MD, MPH, director of the Center for Vaccine Development at the University of Maryland School of Medicine (UM SOM), has received the 2016 Vanderbilt University School of Medicine Distinguished Alumni Award.